文献速递胸部肿瘤放疗放疗物理与技术

基于知识计划识别大于5厘米肺部肿瘤高风险立体定向消融放疗计划

Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-08-14

研究对53例≥5 cm的原发或复发非小细胞肺癌患者(2008–2014年接受5或8次大分割容积调强弧形放疗)进行回顾性分析,30%出现≥3级毒性。利用RapidPlan模型对比有无≥3级毒性患者的剂量学,发现无毒性模型可识别近50%历史计划中剂量学改进空间。

要点

  • ≥5 cm肺肿瘤SABR后30%发生≥3级毒性,包括放射性肺炎、肺出血和气道狭窄/肺不张。
  • 放射性肺炎与对侧肺及全肺V5和平均肺剂量显著相关。
  • 无毒性RapidPlan模型识别出近50%≥3级毒性患者历史计划存在剂量学改进潜力。

核心结论

  • 无毒性RapidPlan模型识别出近50%的≥5 cm肺肿瘤SABR后≥3级毒性患者历史计划存在剂量学改进潜力。
  • 基于模型的QA可能有助于在常规实践和临床研究中基准评估治疗计划协议。

研究设计与样本

  • 回顾性分析53例原发或复发非小细胞肺癌≥5 cm患者,2008–2014年接受5次或8次容积调强弧形放疗SABR。
  • 使用RapidPlan模型(由无毒性且符合当前计划协议的患者计划组成)对出现毒性患者的计划进行QA。

主要发现

  • 53例中16例发生≥3级毒性,包括10例放射性肺炎、3例肺出血(其中1例合并放射性肺炎)和1例气道狭窄/肺不张。
  • 放射性肺炎与对侧肺及全肺V5和平均肺剂量显著相关。
  • 放射性肺炎患者中对侧肺最高剂量见于4例患者。
  • 10例放射性肺炎患者中5例临床计划的对侧肺平均剂量高达知识库计划的2.5倍。
  • 3例肺出血中2例及1例气道狭窄/肺不张患者,临床计划的近端支气管树剂量最高,且高于模型计划。

临床怎么用

  • 基于模型的QA可能有助于在常规实践和临床研究中基准评估治疗计划协议。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic ablative body radiation therapy (SABR) for lung tumors ≥5 cm can be associated with more toxicity than that for smaller tumors. We investigated the relationship between dosimetry and toxicity and used a knowledge-based planning solution to retrospectively perform individualized treatment plan quality assurance (QA) with the aim of identifying where planning could have been improved. METHODS AND MATERIALS: Previous retrospective analysis of 53 patients with primary or recurrent non-small cell lung cancer ≥5 cm, treated with 5- or 8-fraction volumetric modulated arc therapy SABR between 2008 and 2014, showed 30% with grade ≥3 toxicity. During this period, several improvements were made to departmental planning protocols. RapidPlan was used to compare dosimetry of patients with or without grade ≥3 toxicity. A model comprising plans from patients without toxicity and compliant with the current planning protocol was used to provide QA for the plans from patients who had toxicity. RESULTS: Sixteen of 53 patients had grade ≥3 toxicity, including 10 with radiation pneumonitis (RP), 3 with lung hemorrhage (1 of these also had RP), and 1 with airway stenosis/atelectasis. RP was again shown to be significantly correlated with contralateral and total-lung V5 and mean lung dose. The 4 highest contralateral-lung doses belonged to patients with RP. Five of 10 clinical plans in patients with RP had a contralateral-lung mean dose up to 2.5 times higher than that of the knowledge-based plan. For 2 of 3 patients with lung hemorrhage and 1 with airway stenosis/atelectasis, the clinical plans had the highest proximal bronchial tree doses, which was also higher than in plans from the model. In 8 patients with grade ≥3 toxicity, clinical plans had dosimetry similar to that in the predictions from the model. CONCLUSIONS: A "no-toxicity" RapidPlan model identified the potential for dosimetric improvement in nearly 50% of historical treatment plans from patients with grade ≥3 toxicity after SABR for lung tumors ≥5 cm. Model-based QA may be useful for benchmarking treatment planning protocols in routine practice and in clinical studies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hof SV, Delaney AR, Tekatli H, et al. Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm. Int J Radiat Oncol Biol Phys. 2018. PMID: 30114461. doi:10.1016/j.ijrobp.2018.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。